Wurzburg, Germany
Pentixapharm AG is a biotechnology company founded in 2019 and headquartered in Germany. The company is committed to enhancing the lives of patients with malignant diseases by delivering targeted molecular diagnostics and therapies, encapsulated in its slogan: "improves the life of patients with malignant diseases through targeted molecular diagnostic and therapy".
Operating within the Biotechnology, Health Care, Life Sciences, and Pharmaceutical sectors, Pentixapharm AG represents a promising proposition in the rapidly evolving life sciences industry. Their focus on precision medicine underscores its potential for growth and impact in a market increasingly geared towards personalized healthcare solutions.
The company's most recent financial achievement was a €15.00M Series A investment received on 01 February 2020 from the ELSA Eckert Life Science Accelerator. This investment underscores the confidence placed in Pentixapharm AG by notable industry investors, poised to support its advancement in therapeutic and diagnostic innovations.
,-LLC--logo.jpg "Radiopharmaceutical Imaging and Dosimetry (Rapid), LLC"){kind=logo}
